Nasal Photodisinfection COVID-19 Proof of Concept Study
Primary Purpose
COVID-19, Corona Virus Infection, SARS-CoV 2
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Methylene-Blue Photodisinfection
Sponsored by
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, SARS-CoV-2, coronavirus, influenza, photodisinfection, nasal photodisinfection
Eligibility Criteria
Inclusion Criteria (patient population):
- Recent SARS-CoV-2+ diagnosis
- Present in hospital
Inclusion Criteria (healthcare workers):
- Recent SARS-CoV-2+ diagnosis
- Ability to self-administer nasal swabs
Exclusion Criteria (patient population):
- Immediate requirement for intubation (i.e. emergency airway) or inability to maintain independent oral airway
Exclusion Criteria (healthcare workers):
- None
Sites / Locations
- Sunnybrook Health Sciences Centre
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Methylene Blue-Photodisinfection
Arm Description
The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
Outcomes
Primary Outcome Measures
RT-qPCR
The main endpoint is microbiological; RT-qPCR will be conducted on the pre and post treatment swabs and the change in cycle threshold value will be measured
Secondary Outcome Measures
Full Information
NCT ID
NCT04615936
First Posted
November 2, 2020
Last Updated
October 29, 2021
Sponsor
Sunnybrook Health Sciences Centre
1. Study Identification
Unique Protocol Identification Number
NCT04615936
Brief Title
Nasal Photodisinfection COVID-19 Proof of Concept Study
Official Title
Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
October 13, 2020 (Actual)
Primary Completion Date
July 7, 2021 (Actual)
Study Completion Date
October 19, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunnybrook Health Sciences Centre
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study proposes to test photodisinfection (PDF) on SARS-CoV-2 in the nose. The study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in he nostril of patients infected with SARS-CoV-2. Participants are swabbed for SARS-CoV-2 before and after the PDF treatment. For the study, a small group of healthcare workers who have tested positive for SARS-CoV-2 will be included. They will not undergo the treatment but will need to swab their noses multiple times over the next 5 days. This nil group will provide the effect (if any) of swabbing SARS-CoV-2 levels in the nose.
Detailed Description
The study proposes to test photodisinfetion (PDF) on levels of SARS-CoV-2 in the nose. The study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in patients infected with SARS-CoV-2 . Currrently, PDF is being used at some institutions before surgery to lower the risk of postoperative infection. PDF uses a Methylene Blue (MB) nasal spray, followed by 5 minutes of red-light exposure through a small light-diffusing applicator. This will need to be placed into each nostril. Participants are swabbed for SARS-CoV-2 before and after treatment. In addition to the patients testing positive for SARS-CoV-2, there will also be a small group of healthcare workers who have tested positive that will be included. Though they are not undergoing treatment, they will swab their own noses multiple times over a period of 5 days. This will allow us to evaluate the effect (if any) of swabbing on SARS-CoV-2 levels in the nose. The study hypothesis is that MB-mediated PDF will show the ability to kill SARS-CoV-2 which will consequently confirm its efficacy as a first line defense against the virus.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Corona Virus Infection, SARS-CoV 2
Keywords
COVID-19, SARS-CoV-2, coronavirus, influenza, photodisinfection, nasal photodisinfection
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
There is only a single group of patients in the study who will undergo treatment. There is a small sub group/'nil' group of 3 healthcare workers that will not be undergoing the treatment but will instead be doing multiple nasal swabbing in the course of 5 days.
Masking
None (Open Label)
Masking Description
N/A- masking not required
Allocation
N/A
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Methylene Blue-Photodisinfection
Arm Type
Experimental
Arm Description
The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
Intervention Type
Other
Intervention Name(s)
Methylene-Blue Photodisinfection
Intervention Description
Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
Primary Outcome Measure Information:
Title
RT-qPCR
Description
The main endpoint is microbiological; RT-qPCR will be conducted on the pre and post treatment swabs and the change in cycle threshold value will be measured
Time Frame
30 minutes
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (patient population):
Recent SARS-CoV-2+ diagnosis
Present in hospital
Inclusion Criteria (healthcare workers):
Recent SARS-CoV-2+ diagnosis
Ability to self-administer nasal swabs
Exclusion Criteria (patient population):
Immediate requirement for intubation (i.e. emergency airway) or inability to maintain independent oral airway
Exclusion Criteria (healthcare workers):
None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cari Whyne, PhD
Organizational Affiliation
Sunnybrook Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
35304729
Citation
Lobo CS, Rodrigues-Santos P, Pereira D, Nunez J, Trepa JCD, Sousa DL, Lourenco JV, Coelho MF, de Almeida LP, da Cunha JS, Arnaut LG. Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. Photochem Photobiol Sci. 2022 Jun;21(6):1101-1109. doi: 10.1007/s43630-022-00202-6. Epub 2022 Mar 19.
Results Reference
derived
Learn more about this trial
Nasal Photodisinfection COVID-19 Proof of Concept Study
We'll reach out to this number within 24 hrs